目的 探索重组人血管内皮抑素(rhES,商品名恩度)体外对急性白血病细胞生长的抑制作用.方法 应用锥虫蓝拒染法、MTT法、透射电子显微镜(电镜)及Annexin V-FITC/PI双标记流式细胞术等方法 检测rhES体外对正常人及急性白血病患者骨髓原代细胞增殖和凋亡的影响.结果 50、100和200μg/ml rhEs作用HL-60细胞72 h,细胞增殖抑制率分别为11.6%、30.4%和33.5% 100和200μg/ml rhES作用NB4细胞72 h,细胞增殖抑制率分别为12.4%和16.4%,其抑制急性白血病细胞株增殖作用呈浓度及时间依赖性 rhES体外浓度0~400μg/ml对正常人骨髓单个核细胞的生长活性无明显抑制作用 50~200 μg/ml rhES对急性白血病患者原代细胞有抑制生长活性的作用,并且其抑制作用呈浓度及时间依赖性.rhES在体外浓度为100 μg/ml时,与HL-60和NB4细胞作用72 h,透射电镜观察可见典型的细胞凋亡的表现,流式细胞术检测凋亡率分别为19.6%和20.8%.结论 rhES在体外有抑制急性白血病细胞增殖和诱导凋亡的作用,是治疗急性白血病潜在的有效药物.
Objective To explore the in vitro anti-leukemia effect of endostar(recombinant human endostatin, rhES). Methods The anti-leukemia effect of endostar on fresh bone marrow cell from acute leukemia patients and healthy adult was analyzed by typan-blue exclusion assay, MTT assay, transmission electron microscopy and flow cytometry with Annexin V -FITC/PI staining. Results Treatment with endostar at concentrations of 50, 100 and 200 μg/ml for 72 hours could inhibit the proliferation of HL-60 cells. The inhibition rates were 11.6% , 30.4% and 33.5% , respectively. For NB4 cells, the inhibitory rates of 100 and 200 μg/ml endostar were 12. 4% and 16. 4% , respectively. The inhibition of endostar on acute leukemia cells was time and dose dependent, 50 - 200 μg/ml endostar could also inhibit the growth of fresh bone marrow cell from acute leukemia patients. While 0 -400 μg/ml endostar had no significant effect on fresh primary bone marrow cells from healthy adult. 100 μg/ml endostar could induce apoptosis of HL-60 and NB4 cells after treatment for 72 hours. The apoptotic rates of HL-60 and NB4 cells were 19.6% and 20. 8% , respectively. Conclusion Endostar inhibits proliferation of leukemia cells by inducing apoptosis. It might be a potential medication for acute leukemia.